Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching

Annals of the Rheumatic Diseases

Volumn 75, Issue 7, 2016, Pages 1321-1327

  Kubo, Satoshi ^a   Nakayamada, Shingo ^a   Nakano, Kazuhisa ^a   Hirata, Shintaro ^a   Fukuyo, Shunsuke ^a   Miyagawa, Ippei ^a   Hanami, Kentaro ^a   Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; STEROID; STROMELYSIN; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; STOMATITIS; AGED; ARTHRITIS, RHEUMATOID; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ABATACEPT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROPENSITY SCORE; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84940212615     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207784     Document Type: Article

References (33)

1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69: 631-7.
2. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
3. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
4. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67: 1516-23.
5. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
6. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
7. Kubo S, Saito K, Hirata S, et al. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. Mod Rheumatol 2014;24:42-51.
8. Tanaka Y, Kubo S, Yamanaka H, et al. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol 2014;24:754-62.
9. Takeuchi T, Tanaka Y, Amano K, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology (Oxford) 2011;50:1908-15.
10. Estellat C, Ravaud P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med 2012;172:237-44.
11. Rogers AS. Adverse drug events: identification and attribution. Drug Intell Clin Pharm 1987;21:915-20.
12. Connors AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996;276:889-97.
13. Dalen JE, Bone RC. Is it time to pull the pulmonary artery catheter? JAMA 1996;276:916-8.
14. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348:5-14.
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
17. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
18. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
19. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
20. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
21. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
22. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
23. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6.
24. Rothman KJ. Six persistent research misconceptions. J Gen Intern Med 2014;29:1060-4.
25. Vickers AJ, Altman DG. Statistics notes: missing outcomes in randomised trials. BMJ 2013;346:f3438.
26. Papp KA, Fonjallaz P, Casset-Semanaz F, et al. Analytical approaches to reporting long-term clinical trial data. Curr Med Res Opin 2008;24:2001-8.
27. Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis 2012;71:1815-19.
28. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.
29. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54.
30. Canhão H, Rodrigues AM, Mourão AF, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford) 2012;51:2020-6.
31. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007;34:1670-3.
32. Smolen JS, Aletaha D, Grisar JC, et al. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010;69:1058-64.
33. Bafeta A, Dechartres A, Trinquart L, et al. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ 2012;344:e813.